Skip to main content
Thomas Ciulla, MD, Ophthalmology, Indianapolis, IN

ThomasAnthonyCiullaMDMBA

Ophthalmology Indianapolis, IN

Retinal Disease

Retina Specialist, Midwest Eye Institute, Indianapolis, IN

Dr. Ciulla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ciulla's full profile

Already have an account?

  • Office

    Midwest Eye Insitute
    10300 North Illinois Street
    Indianapolis, IN 46290
    Phone+1 317-817-1822
    Fax+1 317-817-1898
  • Is this information wrong?

Summary

  • I am a board certified ophthalmologist and retina specialist, who graduated from Harvard College and from the University of California San Francisco School of Medicine, followed by a residency in Ophthalmology at Harvard Medical School, and then a fellowship in Vitreo-Retinal Diseases and Surgery at Tufts Medical School, Boston.

    I co-directed the Retina Service and Ocular Angiogenesis Research Lab at Indiana University School of Medicine, one of the largest U.S. medical schools, prior to joining Midwest Eye Institute, one of the largest subspecialty eye institutes in the Midwest. In 2015, I earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine, and assumed industry leadership roles of increasing responsibility, as VP at Iveric Bio; VP at Spark Therapeutics to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease; and Chief Medical Officer at Clearside Bio. I remain a Volunteer Clinical Professor of Ophthalmology.

    I serve on the Editorial Board of several ophthalmology journals, and remain an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, the American Academy of Ophthalmology, the American Society of Retina Specialists, and The American Society of Gene and Cell Therapy.

    I have held numerous leadership roles in clinical research, serving as principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials, including trials that led to FDA approval of several new retinal therapies. I have delivered over 200 presentations nationally and internationally, edited textbooks, and co-authored nearly 150 Medline-indexed peer reviewed publications, including the first U.S.-based randomized clinical trial on any intravitreal therapy in neovascular AMD.(https://www.ncbi.nlm.nih.gov/pubmed/10872928)

Education & Training

  • Indiana University, Kelley School of Business
    Indiana University, Kelley School of BusinessMBA, Business of Medicine, Beta Gamma Sigma Honor Society, 2013 - 2015
  • Tufts Medical Center
    Tufts Medical CenterFellowship, Surgical Retina and Vitreous, 1995 - 1996
  • Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School1992 - 1995
  • B I Deaconess Med Ctr
    B I Deaconess Med Ctr1991 - 1992
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 1991
  • Harvard College
    Harvard CollegeB.A, Chemistry, 1982 - 1986

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 1996 - 2025
  • MA State Medical License
    MA State Medical License 1993 - 2004
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Indianapolis Monthly Castle Connolly, 2013
  • American Academy of Ophthalmology 2007 Annual Meeting Scientific Program, 2007
  • Best Paper” Award Treatment of Macular Edema Following Central Retinal Vein Occlusion with Pegaptanib Sodium (Macugent): A One-Year Study, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Squalamine safe, effective when administered with PDT.  
    L. Charters, T.A. Ciulla, Ophthalmology Times, 31(5): 64
  • Drug Delivery to the Posterior Segment.  
    D.K. Kurz, T.A. Ciulla, Retinal Physician, 4(7): 19-23
  • Targeting VEGF, The VEGF Trap Clinical Trials.  
    T.A. Ciulla, Review of Ophthalmology, 12:50-54
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • New therapies for age-related macular degeneration.
    T. A. Ciulla, Clinical Researcher 1: 14-17
  • Where the AMD Clinical Trials Stand.
    T. A. Ciulla, Retinal Insider
  • Trends in treatment of Diabetic Macular Edema.
    T. A. Ciulla, Review of Ophthalmology, 12:92
  • Join now to see all

Lectures

  • A new method for evaluating choroidal blood flow in age-related macular degeneration: area dilution analysis. 
    Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL
  • Molecular Heterogeneity of VEGF-A in the Vitreous of Patients with Proliferative Diabetic Retinopathy. 
    The Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL
  • Ophthalmology Anatomy and Physiology. 
    Eli Lilly and Company
  • Join now to see all

Other

  • Indiana University Retina Review. 
    T. A. Ciulla, R. P. Danis
  • How to manage central serous retinopathy. 
    T. A. Ciulla, Review of Ophthalmology 6: 99-102
  • Do Vitamin Supplements Really Prevent Progression of AMD? 
    T. A. Ciulla, R. Abel, P. S. Bernstein, D. Boyer, F. L. Ferris, Ocular Surgery News
  • Join now to see all

Press Mentions

  • Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMD
    Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMDFebruary 2nd, 2023
  • Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMD
    Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Wet AMDFebruary 2nd, 2023
  • Microinjection via the Suprachoroidal Space: A Review of a Novel Mode of Administration
    Microinjection via the Suprachoroidal Space: A Review of a Novel Mode of AdministrationNovember 1st, 2022
  • Join now to see all

Professional Memberships